Home > Keywords > Thématique > Science

Science

Articles

  • Vect-Horus Strengthens Board of Directors with Appointment of Jean-Christophe Dantonel as New Member
    14 November 2024, by Emmanuelle BETTENDORF

    We’re pleased to welcome Jean-Christophe Dantonel as a new member of the Vect-Horus Board of Directors!
    Dr. Dantonel brings over two decades of profound expertise in biological sciences, project management, and clinical research to his new role.
    “He brings key skills to our company at an important stage of its development, with a combination of clinical research and business experience which will be invaluable as we innovate to develop vectors that facilitate targeting and delivery of (…)

  • 3rd Edition of Translational neuroscience Day : challenges and opportunities
    4 December 2019, by Elodie DORMES

    Michel KHRESTCHATISKY co-founder of Vect-Horus – Director of the UMR7051 Institute of Neurophysiopathology at Aix-Marseille University / CNRS will speak at two sessions of The third edition of “Translational neuroscience Day: challenges and opportunities” co-organized by Dhune and hosted by BioFIT on December 10, 2019.

  • Vect-Horus will join the ARVO Annual Meeting
    17 April 2024, by Emmanuelle BETTENDORF

    We’re excited to present a poster on our targeted drug delivery technology at the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting, taking place in Seattle, WA, USA from May 5-9, 2024.
    The poster is titled “VECTrans® technology: a powerful delivery approach to significantly enhance efficacy of therapeutic oligonucleotides in retina cells”.
    It will be available at ARVO on May 7, 2024, from 3:30pm to 5:15pm PDT Posterboard Number 3992 - B0036 and Session (…)

  • Vect-Horus will join the Single-Domain Antibodies Summit
    14 September 2023, by Emmanuelle BETTENDORF

    Vect-Horus Vector Discovery Team will attend the Single Domain Antibodies Summit that will be held in Paris from 18th to 20th of September 2023.
    Interesting sessions are planned and Vect-Horus will attend the one dedicated to “Single domain Antibodies engineering and structure” and of course “Single domain Antibodies in neurobiology”.
    We look forward to discussing with the scientific community attending this meeting and sharing with them our last advances in the use of nanobodies as (…)

  • Society for the study of Blood-Brain interfaces SEISC 2019 congres
    27 November 2019, by Elodie DORMES

    Stéphane GIRARD will present iPS cell-derived model of the human blood-brain-barrier on Friday 15, Nov Session 1 of the Society for the study of Blood-Brain interfaces SEISC 2019 congres in Paris

  • Vect-Horus will attend the Biorezo “Nouvelles technologies de vectorisation, perspectives pour les biotechs et pharma”
    18 October 2022, by Elodie DORMES

    We are pleased to announce that Marion DAVID will be giving a talk entitled “Développement de vecteurs moléculaires pour l’adressage ciblé de molécules d’intérêt thérapeutique” during the Biorezo organized by Eurobiomed in Toulouse on October 18th.

  • Vect-Horus will participate to the event “Espace & Santé” co-organized by CNES, Region Paca and DHUNE on March 29, 2022
    28 October 2020, by Elodie DORMES

    Michel KHRESTCHATISKY will be part of the roundtable 4 and will present the company latest results in connection with “Maintaining and increasing performance – intelligent human machine interfaces, brain tech, exoskeletons, human factor, psychology… ”
    You can access to the program by following the link: https://sante-espace.com/

  • Meet Vect-Horus at 3rd Oligonucleotides for CNS Summit in Boston June 6-8th, 2023
    30 June 2023, by Elodie DORMES

    Meet with Michel KHRESTCHATISKY and Guillaume JACQUOT at the 3rd Oligonucleotides for CNS Summit 2023, dedicated to optimizing antisense and RNA chemistry for brain delivery, in Boston from June 6-8th, 2023.

  • Neurotensin, vectorised by VECT-HORUS, is the first drug-candidate in neuroprotective hypothermia
    28 January 2019, by Jonathan NOWAK

    VECT-HORUS starts the regulatory preclinical development of VH-N439, positioned as a first-in-class neuroprotective agent in brain ischemia Neurotensin is a neuropeptide with global hypothermic potential when administered directly into the brain, but unable to cross the blood-brain barrier (BBB) when administrated alone systemically. The Company has developed VH-N439, a new chemical entity based on the conjugation of one of its peptide-vectors to an analogue of neurotensin.
    Using in vivo (…)

  • Séminaire M&M’s – Muscle Monday Seminars of the Institute’s Myology Centre for Research on January 17, 2022
    17 January 2022, by Elodie DORMES

    Michel Khrestchatisky (CNRS Research Director, Director of the Institute for Neurophysiopathology) Co-Founder & Scientific Counsel of Vect-Horus presents "Development of molecular vectors for targeted delivery of RNAi via receptor-mediated transport" at the Muscle Monday Seminars organized by the Institute’s Myology Centre for Research.